Immunodiagnostic Systems Holdings PLC develops, manufactures, and sells in-vitro diagnostic tests to the clinical laboratory market in the United Kingdom, the United States, Germany, France, and internationally. More Details
Flawless balance sheet and overvalued.
Share Price & News
How has Immunodiagnostic Systems Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IDH is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: IDH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
7 Day Return
GB Medical Equipment
1 Year Return
GB Medical Equipment
Return vs Industry: IDH exceeded the UK Medical Equipment industry which returned 6.5% over the past year.
Return vs Market: IDH underperformed the UK Market which returned 27.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Immunodiagnostic Systems Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StImmunodiagnostic Systems Holdings (LON:IDH) Share Prices Have Dropped 13% In The Last Year
4 months ago | Simply Wall StA Quick Analysis On Immunodiagnostic Systems Holdings' (LON:IDH) CEO Salary
5 months ago | Simply Wall StIs Immunodiagnostic Systems Holdings PLC (LON:IDH) A Good Fit For Your Dividend Portfolio?
Is Immunodiagnostic Systems Holdings undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: IDH (£2.55) is trading above our estimate of fair value (£0.41)
Significantly Below Fair Value: IDH is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: IDH is poor value based on its PE Ratio (193.2x) compared to the UK Medical Equipment industry average (48.2x).
PE vs Market: IDH is poor value based on its PE Ratio (193.2x) compared to the UK market (25.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IDH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IDH is good value based on its PB Ratio (1.4x) compared to the GB Medical Equipment industry average (3.7x).
How is Immunodiagnostic Systems Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immunodiagnostic Systems Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Immunodiagnostic Systems Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IDH has a large one-off gain of £670.0K impacting its September 30 2020 financial results.
Growing Profit Margin: IDH's current net profit margins (1.1%) are lower than last year (2.9%).
Past Earnings Growth Analysis
Earnings Trend: IDH has become profitable over the past 5 years, growing earnings by 66.3% per year.
Accelerating Growth: IDH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: IDH had negative earnings growth (-66.3%) over the past year, making it difficult to compare to the Medical Equipment industry average (13.8%).
Return on Equity
High ROE: IDH's Return on Equity (0.7%) is considered low.
How is Immunodiagnostic Systems Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: IDH's short term assets (£46.5M) exceed its short term liabilities (£8.6M).
Long Term Liabilities: IDH's short term assets (£46.5M) exceed its long term liabilities (£5.2M).
Debt to Equity History and Analysis
Debt Level: IDH is debt free.
Reducing Debt: IDH currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Debt Coverage: IDH has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: IDH has no debt, therefore coverage of interest payments is not a concern.
What is Immunodiagnostic Systems Holdings's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: IDH's dividend (0.75%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.37%).
High Dividend: IDH's dividend (0.75%) is low compared to the top 25% of dividend payers in the UK market (4.09%).
Stability and Growth of Payments
Stable Dividend: IDH is not paying a notable dividend for the UK market, therefore no need to check if payments are stable.
Growing Dividend: IDH is not paying a notable dividend for the UK market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: IDH is not paying a notable dividend for the UK market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IDH's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jaap Stuut (50 yo)
Mr. Jaap Stuut has been the Chief Executive Officer of Immunodiagnostic Systems Holdings PLC since November 1, 2017. Mr. Stuut has been with the Immunodiagnostic Systems Holdings PLC since 2013 and was pre...
CEO Compensation Analysis
Compensation vs Market: Jaap's total compensation ($USD400.19K) is about average for companies of similar size in the UK market ($USD338.89K).
Compensation vs Earnings: Jaap's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: IDH's management team is seasoned and experienced (5.3 years average tenure).
Experienced Board: IDH's board of directors are considered experienced (5.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Immunodiagnostic Systems Holdings PLC's company bio, employee growth, exchange listings and data sources
- Name: Immunodiagnostic Systems Holdings PLC
- Ticker: IDH
- Exchange: AIM
- Founded: 1977
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: UK£73.399m
- Shares outstanding: 28.78m
- Website: https://www.idsplc.com
Number of Employees
- Immunodiagnostic Systems Holdings PLC
- Boldon Business Park
- 10 Didcot Way
- Tyne and Wear
- NE35 9PD
- United Kingdom
Immunodiagnostic Systems Holdings PLC develops, manufactures, and sells in-vitro diagnostic tests to the clinical laboratory market in the United Kingdom, the United States, Germany, France, and internatio...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 20:03|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.